Vertex Pharmaceuticals (VRTX), Thursday announced a reimbursement agreement with the Italian Medicines Agency that allows eligible transfusion-dependent beta thalassemia and severe sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy CASGEVY.
CASGEVY, a non-viral ex vivo CRISPR/Cas9 gene-edited cell therapy, is designed to produce high levels of fetal hemoglobin in red blood cells, reducing or eliminating vaso-occlusive crises for SCD patients and transfusion needs for TDT patients.
VRTX is currently trading at $387.05, down $0.10 or 0.03 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.